A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia.
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2014
At a glance
- Drugs Monascus (Primary)
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- Sponsors Beijing Peking University WBL Biotech
- 10 Jun 2017 Biomarkers information updated
- 01 Jun 2012 Planned End Date changed from 1 Dec 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov record.
- 01 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History